



(51) International Patent Classification:

C07D 403/04 (2006.01) A61K 31/506 (2006.01)
A61P 11/06 (2006.01)

(21) International Application Number:

PCT/EP2019/069252

(22) International Filing Date:

17 July 2019 (17.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/699955 18 July 2018 (18.07.2018) US
62/866013 25 June 2019 (25.06.2019) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).(72) Inventors: **PETTERSEN, Anna, Matilda, Angelica**; AstraZeneca Pepparedsleden 1, SE-431 50 Mölndal (SE). **MC-CABE, James**; AstraZeneca UK Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **AURELL, Carl-Johan**; AstraZeneca Pepparedsleden 1, SE-431 50 Mölndal (SE).(74) Agent: **WINSHIP, Emma, Victoria, Bristowe, Wallace**; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: A XINAFOATE SALT OF A JAK INHIBITING COMPOUND





Figure 1

XRPD of 4-[(2R)-1-[(3-[5-fluoro-2-[2-fluoro-3-(methanesulfonyl)anilino]pyrimidin-4-yl)-1H-indol-7-yl]amino]-3-methoxy-1-oxopropan-2-yl]-1-methylpiperazin-1-ium; 1-hydroxynaphthalene-2-carboxylate



(57) Abstract: The present disclosure relates to salts of compounds of Formula (I) prepared as a xinafoate (1-hydroxy-2-naphthoate) salt (Formula (Ia)), pharmaceutically acceptable compositions comprising same and methods of using the same.

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*